CJC-1295 + Ipamorelin 5/5mg

CJC-1295 without DAC 5mg + IPA 5mg

🔬 CJC-1295 + Ipamorelin Stack — Overview

CJC-1295 + Ipamorelin refers to a research peptide combination of two distinct growth hormone–releasing agents that are commonly paired in laboratory and investigative contexts to boost natural growth hormone (GH) secretion more effectively than either peptide alone. CJC-1295 acts on the growth hormone–releasing hormone (GHRH) receptor, while ipamorelin acts as a ghrelin receptor agonist (growth hormone secretagogue) — together they synergize to enhance both the magnitude and duration of GH pulses from the pituitary gland.

⚠️ Important: This stack is a combination of separate peptides, not a single new chemical entity. They are typically provided as separate lyophilized powders and can be co-administered in research protocols rather than chemically fused.

🧪 Component A — CJC-1295 (with or without DAC)

📌 Functional Summary

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release endogenous GH. When formulated with a Drug Affinity Complex (DAC), its half-life is significantly extended due to albumin binding, leading to prolonged GH stimulation compared with unmodified forms.

🔢 CAS Number

• 863288-34-0 — widely cited for CJC-1295 (with DAC).

🧬 Molecular Formula

• C₁₆₅H₂₆₉N₄₇O₄₆ — for the DAC-modified peptide form.

⚖️ Molecular Weight

• ≈3,647.9 g/mol (Da) — approximate peptide mass with DAC modification.

🧬 Sequence & Structure

• CJC-1295 is a modified GHRH analog (~30 amino acids) with substitutions designed to enhance receptor affinity and stability and, when with DAC, includes a maleimidopropionyl group facilitating albumin binding.

🧪 Component B — Ipamorelin

📌 Functional Summary

Ipamorelin is a pentapeptide growth hormone secretagogue that binds to ghrelin receptors, stimulating a rapid, pulsatile release of GH with minimal effects on cortisol or prolactin — often described as a “clean” GH secretagogue.

🔢 CAS Number

• 170851-70-4 — the registered CAS number for ipamorelin.

🧬 Molecular Formula

• C₃₈H₄₉N₉O₅ — elemental composition of the peptide.

⚖️ Molecular Weight

• ≈711.9 g/mol (Da) — approximate peptide mass.

🧬 Sequence & Structure

• Aib-His-D-2Nal-D-Phe-Lys-NH₂ — a synthetic five-amino-acid peptide with structural motifs that confer high affinity for the ghrelin receptor.

🧠 Mechanisms & Research Context

• Synergistic GH Stimulation: CJC-1295 acts on the GHRH receptor to promote sustained, long-lasting GH release. Ipamorelin acts on the ghrelin receptor to trigger rapid, high-amplitude bursts of GH — the combination mimics a more physiologic GH secretory pattern through distinct receptor pathways.
• Research Applications: This stack is often used in research on endocrine regulation, body composition, recovery, and metabolic signaling, capitalizing on the complementary mechanisms of action.
• Not a New Molecule: In experimental protocols, researchers typically reconstitute each peptide separately and co-administer them in a study rather than chemically linking them into a single compound.

⚠️ Safety & Regulatory Notes

• Research-Use Only: Both CJC-1295 and ipamorelin are typically supplied as research peptides and are not approved as therapeutic drugs by regulatory authorities.
• Effects such as changes in growth hormone (GH) and insulin-like growth factor-1 (IGF-1) can have wide systemic implications; interpretation should remain within experimental frameworks only.

🧪 Quick Reference Summary